PATENT CLAIM ANALYSIS

Application Number: 16364463
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "289000"]

Abstract:
Described herein are dosage forms of enantiomerically enriched (S)-bupropion or enantiomerically enriched (R)-bupropion. The (S)-bupropion or the (R)-bupropion may be deuterium enriched, or may have natural isotopic abundance. These dosage forms may be administered, either fed or fasted, to treat a condition recited herein, to achieve a certain pharmacokinetic parameter of a bupropion or a metabolite of a bupropion, and/or to enhance dextromethorphan plasma levels.

Claim (Index 14):
A method of delivering a pharmacokinetic equivalent of oral racemic bupropion to the plasma of a human being comprising: orally administering a dosage form containing (S)-bupropion that is at least 95% enantiomerically pure to the human being so that the human being receives a first amount of (S)-bupropion, wherein the AUC 0-12  of hydroxybupropion is within 20% of the C max  of (R,R)-hydroxybupropion that would result from administering racemic bupropion to the human being in an amount that is twice the first amount of (S)-bupropion.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 99.0
- Lexical Diversity: 1.84783
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14997316', '15164767', '15130807', '15599163', '14617624']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8393146217014079
- 35 USC 102 Novelty (BERT): 0.548857748475353
- Combined Prediction Score: 0.8102689343788024
- Mean Citation Score: 445.30945200000014
- Max Citation Score: 450.97195
- Similarity Product: 336.538020900473

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test